CORE-010: MEDICINAL CHEMISTRY SHARED RESOURCE (MCSR) PROJECT SUMMARY / ABSTRACT The Medicinal Chemistry Shared Resource (MCSR) is critical to the OSUCCC drug development mission supporting preclinical studies leading to more rationale clinical trial designs and effective cancer therapies. Established during the last grant application as a developing shared resource, the MCSR is now being proposed as a formal shared resource. The MCSR's Senior Faculty Advisor is Dr. Ching-Shih Chen, a highly accomplished medicinal chemist, who established the MCSR as the director. The director of the MCSR is now Dr. Chad Bennett, a recent recruit, who is an experienced medicinal and process chemist with industry experience. The MCSR has three Specific Aims: 1) to custom-synthesize new agents to improve cancer therapeutics; 2) to synthesize agents for cancer researchers needing compounds that are not available; and, 3) lead optimization by conducting structure-activity relationship (SAR) analyses and structure-based design. To accomplish these aims, the MCSR integrates the expertise of multiple disciplines, including medicinal chemistry, process chemistry, computational chemistry, structural biology and molecular pharmacology. The MCSR is located in the 4th floor of Biomedical Research Tower, in close proximity to most OSUCCC investigators. Since 2011, when the MCSR was established, the MCSR has provided chemical synthesis services to 32 OSUCCC investigators, 9 investigators from other NCI-sponsored institutions, and has synthesized 33 compounds that were otherwise not available from commercial sources or were cost prohibitive. These agents have helped investigators to conduct proof-of-concept in vitro and/or in vivo preclinical experiments that have aided in a better understanding of cancer biology and led to rationale clinical trial development. The MCSR has contributed to 63 publications over the last grant period, 6 of which were in journals with an impact factor >10, and it has supported 6 NCI grants (not including services provided for 9 other NCI Cancer Centers). The future plans are to build a formal partnership with the OSUCCC's Drug Development Institute and to increase services for lead optimization. The MCSR leverages extensive institutional support, and seeks only 15.4% support from CCSG funds. The Medicinal Chemistry Shared Resource is part of the Analytics Grouping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-41
Application #
9221255
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
41
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
Barajas, Juan M; Reyes, Ryan; Guerrero, Maria J et al. (2018) The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep 8:9105

Showing the most recent 10 out of 2602 publications